Almotriptan
|
The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.
|
Altretamine
|
Risk of severe hypotension
|
Amitriptyline
|
Possibility of severe adverse effects
|
Amoxapine
|
Possibility of severe adverse effects
|
Amphetamine
|
Possible hypertensive crisis
|
Atomoxetine
|
Possible severe adverse reaction with this combination
|
Benzphetamine
|
MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
|
Bezafibrate
|
MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid.
|
Brimonidine
|
MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
|
Buprenorphine
|
Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
|
Bupropion
|
Possible severe adverse reaction with this combination
|
Buspirone
|
Possible blood pressure elevation
|
Citalopram
|
Possible severe adverse reaction with this combination
|
Clomipramine
|
Possibility of severe adverse effects
|
Desipramine
|
Possibility of severe adverse effects
|
Desvenlafaxine
|
Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
|
Dexfenfluramine
|
Risk of hypertensive crisis.
|
Dextroamphetamine
|
Possible hypertensive crisis
|
Dextromethorphan
|
Possible severe adverse reaction
|
Diethylpropion
|
Possible hypertensive crisis
|
Dobutamine
|
Increased arterial pressure
|
Donepezil
|
Possible antagonism of action
|
Dopamine
|
Increased arterial pressure
|
Doxepin
|
Possibility of severe adverse effects
|
Duloxetine
|
Possible severe adverse reaction with this combination
|
Entacapone
|
Possible hypertensive crisis with this combination
|
Ephedra
|
Increased arterial pressure
|
Ephedrine
|
Increased arterial pressure
|
Epinephrine
|
Increased arterial pressure
|
Escitalopram
|
Possible severe adverse reaction with this combination
|
Fenfluramine
|
Possible hypertensive crisis
|
Fenoterol
|
Increased arterial pressure
|
Fluoxetine
|
Possible severe adverse reaction with this combination
|
Fluvoxamine
|
Possible severe adverse reaction with this combination
|
Galantamine
|
Possible antagonism of action
|
Guanethidine
|
Isocarboxazid may decrease the effect of guanethidine.
|
Imipramine
|
Possibility of severe adverse effects
|
Isoproterenol
|
Increased arterial pressure
|
L-Tryptophan
|
Possible severe adverse reaction with this combination
|
Levodopa
|
Possible hypertensive crisis
|
Mazindol
|
Possible hypertensive crisis
|
Meperidine
|
Potentially fatal adverse effects
|
Mephentermine
|
Increased arterial pressure
|
Metaraminol
|
Increased arterial pressure
|
Methamphetamine
|
Possible hypertensive crisis
|
Methotrimeprazine
|
Possible severe adverse reaction with this combination
|
Methoxamine
|
Increased arterial pressure
|
Methylphenidate
|
Possible hypertensive crisis with this combination
|
Midodrine
|
Possible hypertensive crisis with this combination
|
Milnacipran
|
Increase serotonin levels. Combination therapy is contraindicated.
|
Mirtazapine
|
Possible severe adverse reaction with this combination
|
Naratriptan
|
The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
|
Nefazodone
|
Possible severe adverse reaction with this combination
|
Norepinephrine
|
Increased arterial pressure
|
Nortriptyline
|
Possibility of severe adverse effects
|
Orciprenaline
|
Increased arterial pressure
|
Paroxetine
|
Possible severe adverse reaction with this combination
|
Phendimetrazine
|
Possible hypertensive crisis
|
Phenmetrazine
|
Possible hypertensive crisis
|
Phentermine
|
Possible hypertensive crisis
|
Phenylephrine
|
Increased arterial pressure
|
Phenylpropanolamine
|
Increased arterial pressure
|
Pirbuterol
|
Increased arterial pressure
|
Procaterol
|
Increased arterial pressure
|
Protriptyline
|
Possibility of severe adverse effects
|
Pseudoephedrine
|
Increased arterial pressure
|
Rivastigmine
|
Possible antagonism of action
|
Rizatriptan
|
The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
|
Salbutamol
|
Increased arterial pressure
|
Sertraline
|
Possible severe adverse reaction with this combination
|
Sibutramine
|
Possible serotoninergic syndrome with this combination
|
Sumatriptan
|
The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.
|
Tacrine
|
The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
|
Terbutaline
|
Increased arterial pressure
|
Tetrabenazine
|
Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated.
|
Tolcapone
|
Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
|
Tramadol
|
Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.
|
Tranylcypromine
|
Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
|
Trazodone
|
Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
|
Trimethobenzamide
|
Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
|
Trimipramine
|
Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
|
Triprolidine
|
Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
|
Trospium
|
Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
|
Venlafaxine
|
Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
|
Vilazodone
|
MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
|
Zolmitriptan
|
The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.
|